Table 4.
Studies of Apheresis for Treatment of Crohn’s Disease
| Reference | N | System | Results |
|---|---|---|---|
| Kosaka et al67 | 18 | Cellsorba | 5 weekly sessions then 5 monthly sessions: 9 remissions, 14 improved CDAI, IOIBD |
| Matsui et al68 | 7 | Adacolumn | 5 entered remission |
| Kosaka et al69 | 6 | Adacolumn | 3 improved, 1 in remission after 5 weekly sessions then 2 sessions; IBDQ improvement |
| Fukuda et al70 | 21 | Adacolumn | “Improved” symptoms on CDAI, IBDQ, IOIBD at wk 7 |
| Sands et al47 | 15 | Adacolumn | 8 responded to 5 sessions, 5 entered remission; IBDQ improvement noted |
| Maiden et al71 | 13 | Adacolumn | 8/13 maintained remission after 5 sessions vs 14/17 controls; time to relapse: 181 days vs 104 days for controls |
CDAI=Crohn’s Disease Activity Index; IBDQ=Inflammatory Bowel Disease Questionnaire; IOIBD=International Organization for the Study of Inflammatory Bowel Disease.